Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Etigilimab + Nivolumab for Ovarian Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing the combination of two drugs, etigilimab and nivolumab, in patients whose ovarian, peritoneal, or fallopian tube cancer has returned and does not respond to other treatments. These drugs help the immune system fight cancer and stop it from growing. The goal is to see if this combination can better control the cancer and understand its effects on the immune system.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service